Hetrazan 100 Tablet contains Diethylcarbamazine 100 mg, an anthelmintic agent primarily used in the treatment and prevention of filarial infections caused by Wuchereria bancrofti, Brugia malayi, and Loa loa. Diethylcarbamazine acts by altering the surface membrane of microfilariae, rendering them more susceptible to immune attack and facilitating their clearance from the bloodstream. Hetrazan is indicated for lymphatic filariasis, loiasis, and tropical eosinophilia. The recommended dosage varies depending on the specific infection and patient weight, typically administered orally once or multiple times daily for a prescribed duration. Common side effects may include headache, dizziness, nausea, and mild gastrointestinal disturbances; more severe reactions such as allergic responses or encephalopathy are rare but require immediate medical attention. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with known hypersensitivity to Diethylcarbamazine. Monitoring during therapy is recommended to assess efficacy and detect adverse effects. Hetrazan should be used under medical supervision, with adherence to prescribed dosage and duration to ensure optimal therapeutic outcomes and minimize the risk of resistance or relapse.